These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 29998227)

  • 1. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
    Cho JC; Le AD; Locke SC
    Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
    Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
    N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
    Hecke SV; Calcoen B; Lagrou K; Maertens J
    Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letermovir: First Global Approval.
    Kim ES
    Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
    Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
    Clin Drug Investig; 2024 Jul; 44(7):527-540. PubMed ID: 38935253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
    Foolad F; Aitken SL; Chemaly RF
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
    Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.
    Desai N; Pasic I; Law AD; Lam W; Gerbitz A; Viswabandya A; Kim DD; Kumar R; Mattsson J; Novitzky-Basso I; Michelis FV
    Eur J Haematol; 2024 Oct; 113(4):477-484. PubMed ID: 39031870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letermovir for the management of cytomegalovirus infection.
    Bowman LJ; Melaragno JI; Brennan DC
    Expert Opin Investig Drugs; 2017 Feb; 26(2):235-241. PubMed ID: 27998189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letermovir at a Prophylactic Dose for Cytomegalovirus Infection in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study in Japan.
    Tatebe Y; Manabe Y; Tanaka Y; Shiwaku T; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Washio K; Hamano H; Murakawa K; Zamami Y
    Biol Pharm Bull; 2024; 47(9):1575-1582. PubMed ID: 39343543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
    Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
    Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
    Groll AH; Schulte JH; Antmen AB; Fraser CJ; Teal VL; Haber B; Caro L; McCrea JB; Fancourt C; Patel M; Menzel K; Badshah C
    Pediatr Infect Dis J; 2024 Mar; 43(3):203-208. PubMed ID: 38241643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
    Gagelmann N; Ljungman P; Styczynski J; Kröger N
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2101-2109. PubMed ID: 29777868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
    Douglas CM; Barnard R; Holder D; Leavitt R; Levitan D; Maguire M; Nickle D; Teal V; Wan H; van Alewijk DCJG; van Doorn LJ; Chou S; Strizki J
    J Infect Dis; 2020 Mar; 221(7):1117-1126. PubMed ID: 31781762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letermovir (Prevymis) for CMV prophylaxis.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):199-201. PubMed ID: 31999668
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.